Advertisement

PentaVision

Retinal Physician

Article | 2025 American Society of Retina Specialists Annual Meeting

Oral Gildeuretinol Slows Stargardt Progression

Interim data from TEASE‑3 presented at ASRS show stabilization of vision and retinal structure in patients with early-stage disease.

By: Jim Gallagher, senior managing editor
Retinal Physician August 1, 2025 Vol 22, Issue July/August 2025

Clinical Report: Oral Gildeuretinol Slows Stargardt Progression

Overview

Interim data from the TEASE-3 study indicate that oral gildeuretinol may stabilize vision and slow retinal degeneration in children and adolescents with early-stage Stargardt disease. The findings suggest a significant difference in disease progression compared to untreated siblings.

Background

Stargardt disease, caused by mutations in the ABCA4 gene, leads to the accumulation of toxic retinal byproducts, resulting in vision loss. Current treatment options are limited, making the exploration of new therapies like gildeuretinol critical for preserving vision in affected patients. The TEASE-3 study aims to evaluate the efficacy of gildeuretinol in a pediatric population, addressing an urgent need for effective interventions.

Data Highlights

ParameterGildeuretinol GroupSiblings (Control)
Visual Acuity StabilityStableGradual Loss
EZ Area LossMinimal IncreaseIncreased Loss
Fundus AutofluorescenceStableIncreased Atrophy
Serious Adverse EventsNoneN/A

Key Findings

  • Gildeuretinol treatment resulted in stable visual acuity over 24 months.
  • Patients showed slower anatomic degeneration compared to historical sibling controls.
  • Ellipsoid zone area loss was reduced in treated patients.
  • No serious adverse events were reported during the study.
  • Systemic monitoring indicated no significant changes in liver function or lipid levels.

Clinical Implications

The findings from the TEASE-3 study suggest that gildeuretinol may provide a new therapeutic option for children and adolescents with early-stage Stargardt disease. Clinicians should consider the potential benefits of gildeuretinol in preserving vision and slowing disease progression in this patient population.

Conclusion

Oral gildeuretinol shows promise in stabilizing vision and slowing retinal degeneration in early-stage Stargardt disease. Further studies are warranted to confirm these findings and assess long-term outcomes.

References

  1. Ophthalmology Management, 2024 -- Gildeuretinol Acetate Reduces GA Lesion Growth
  2. Retinal Physician, 2025 -- Alkeus Pharmaceuticals ARVO Gildeuretinol GA Data
  3. Ophthalmology Management, 2025 -- Alkeus ARVO Gildeuretinol GA Data
  4. Ophthalmology Management, 2018 -- Update on Stargardt disease
  5. EURETINA IRD Consensus Supplement, 2025
  6. Retinal Physician, 2025 -- Oral Gildeuretinol Slows Stargardt Progression
  7. Retinal Physician, 2025 -- Tinlarebant Shows Benefit in Stargardt Trial
  8. https://eplatform.euretina.org/wp-content/uploads/2025/10/EURETINA_IRD-Consensus-Supplement.pdf
  9. Oral Gildeuretinol Slows Stargardt Progression | Retinal Physician
  10. Tinlarebant Shows Benefit in Stargardt Trial | Retinal Physician